This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: May 17, 2012
Last updated: April 9, 2017
Last verified: April 2017

This is a multicentre, open label study to examine the effect of ezogabine/retigabine on the voiding function of adult subjects with drug-resistant partial onset seizures (POS). Subjects fulfilling the study entry criteria at Screening and at Baseline including a comprehensive eye examination by an ophthalmologist or retina specialist and a skin assessment by the investigator will receive ezogabine/retigabine.

The starting dose of ezogabine/retigabine will be 300 mg/day. Subjects will be up titrated by 150 mg/day weekly up to the maximum ezogabine/retigabine daily dose of 1200 mg (or the highest tolerated dose). During the 49 days of the treatment phase, subjects will undergo three repeat non-invasive assessments of voiding function. In addition, subjects who meet pre-determined criteria for voiding dysfunction will undergo multichannel cystometry in order to characterise bladder hypocontractility, bladder outlet obstruction or a combination of events which clinically is manifest with difficulty emptying the bladder or acute urinary retention.

At the end of the Treatment Phase, all subjects will enter the Taper Phase, a 3-week down titration period. Subjects who have new findings of abnormal pigmentation of the retina, unexplained vision loss, pigmentation of non-retinal ocular tissue or discoloration of skin, lip, nail, or mucosa since baseline will be asked to enter the Safety Follow-Up / Continuation Phase. All subjects will undergo 6-monthly comprehensive eye examinations during the Safety Follow-Up / Continuation Phase. Subjects who have not developed abnormal discoloration of the skin, lips, nails or mucosa will continue to undergo skin assessments by the investigator. Any subject who has developed abnormal discoloration of the skin, lips, nails or mucosa since baseline will be referred to a dermatologist for evaluation and 6-monthly follow up assessments. All subjects will continue to be followed until the pigmentation and/or discoloration has resolved or stabilised, as defined by no change over 2 consecutive 6-monthly assessments conducted over at least 12 months after discontinuation of ezogabine/retigabine.

Condition Intervention Phase
Epilepsy Drug: ezogabine/retigabine Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Uroflowmetry: change from baseline in Maximum Flow Rate (Qmax) at Visit 5. [ Time Frame: Day 49 ]

Secondary Outcome Measures:
  • Uroflowmetry: change from baseline in Maximum Flow Rate (Qmax) at Visits 3, 4 and 6. [ Time Frame: Day 21, 35 and 70 ]
  • PVR Bladder Ultrasound: change from baseline in % Residual Urinary Volume (RUV) at Visits 3, 4, 5 and 6. [ Time Frame: Day 21, 35, 49 and 70 ]
  • Uroflowmetry: change from baseline in Voided Volume (VV), Time to Maximum Flow, Flow Time baseline, and Average Flow Rate (Qmean) at each post-baseline visit. [ Time Frame: Day 21-70 ]
  • Voiding Diary: frequency of micturition and volume voided as recorded on the Voiding Diary for 2 days prior to each post-baseline visit. [ Time Frame: Day 21-70 ]
  • AUA Symptom Index: change from baseline in the America Urological Association Symptom Index (AUA SI) at each post-baseline visit. [ Time Frame: Day 21-70 ]

Enrollment: 10
Actual Study Start Date: March 27, 2013
Study Completion Date: November 16, 2016
Primary Completion Date: November 16, 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ezogabine/retigabine
Drug: ezogabine/retigabine
Starting dose of 300mg/day, titrate up to a targeted maximum dose of 1200 mg/day. Dose can be reduced to a minimum of 600 mg/day if unable to tolerate higher doses


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Is ≥18 years of age (male or female).
  • Has a confident diagnosis of epilepsy with partial onset seizures with or without secondary generalization (classified according to International League Against Epilepsy (ILAE) Guidelines, 1981) ≥ 2 years.
  • Is currently being treated with a stable regimen of one to three AEDs during the 4 weeks prior to the Screening Visit.
  • Following Amendment 03: must be considered drug resistant, consistent with the definition proposed by Kwan, et al 2010 [Kwan].
  • Note: Vagus Nerve Stimulator (VNS), VNS will not be counted as a concurrent AED. Subjects with surgically implanted VNS will be allowed to enter the study provided that all of the following conditions are met:
  • The VNS has been in place for at least 24 weeks prior to the Screening Visit
  • The settings must remain the same for at least 4 weeks prior to the Screening Visit and throughout the study
  • The battery is expected to last for the duration of the study
  • Subject who are considering implantation of a VNS are excluded from participating in this study
  • Note: The chronic use of benzodiazepines as a concurrent AED is permitted as long as the dose is kept constant for at least 4 weeks before the Screen Visit and throughout the study.
  • Is able and willing to maintain an accurate and complete a two (2) day Voiding Diary at protocol specified time points.
  • Is able and willing to maintain an accurate and complete daily written Seizure Calendar at specified time points or has a caregiver who is able and willing to maintain an accurate and complete daily written Seizure Calendar for the entire duration of the study.
  • Has given written informed consent, prior to the performance of any study assessments.
  • A female subject is eligible to enter and participate in the study if she is not pregnant or lactating or planning to become pregnant during the study and is of:
  • Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is pre-menarchal or post-menopausal).
  • Pre-menopausal females with a documented (medical report verification) hysterectomy with or without oophorectomy or bi-lateral oophorectomy when reproductive status has been confirmed by hormone level assessment
  • Post-menopausal females defined as being amenorrhoeic for greater than one year with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms). However, if indicated, this should be confirmed by oestradiol and follicle stimulating hormone (FSH) levels consistent with menopause (according to local laboratory ranges).
  • Women who have not been confirmed as post-menopausal should be advised to use contraception as outlined in Appendix 2.
  • Child-bearing potential, has a negative pregnancy test at screening and baseline, and agrees to satisfy one of the requirements in as listed in Appendix 2.
  • Liver function tests: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2 x upper limit of normal (ULN); alkaline phosphatase and bilirubin less than or equal to 1.5 x ULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
  • Has a normal creatinine clearance (age corrected) as calculated with the Cockcroft-Gault formula.

Exclusion Criteria:

  • Has generalized epilepsy (e.g., Lennox-Gastaut, Juvenile Myoclonic epilepsy, Absence, etc).
  • Has had status epilepticus (other than simple partial status epilepticus) within the 12 months prior to Screening or during the Baseline Phase.
  • Has a history of innumerable seizures within the 12 months prior to Screening where the individual seizures cannot be counted.
  • Has a history of pseudo seizures, non-epilepsy events or any other type of psychogenic seizures that could be confused with seizures.
  • Acute Urinary Retention (treated or untreated) within 6 months of screening or an episode of Acute Urinary Retention (treated) within the last two years with symptoms within the last 6 months.
  • Screening AUA SI Score >7 (>11 for subject over 55 years old).
  • Flowmetry Peak Flow < 15mL/sec out of a urine volume void of 150mL (<11 mL/sec for subject over 55 years old) at Screening.
  • PVR >125mL or >40% functional residual volume at Screening.
  • Prior history of administration of Botox® within genitourinary system.
  • Prior history or any type of medical or surgical therapy for urinary incontinence.
  • Prior history of treated or untreated, bladder, prostate, uterine or cervical cancer.
  • Use of sildenafil, tadalafil, vardenafil or other PDE-5 inhibitors within 2 weeks of study start.
  • Use of α-adrenoreceptor antagonists within 2 weeks of study start.
  • Has had previous exposure to ezogabine/retigabine.
  • Is currently or has been abusing substance(s) or any medications in the 12 months prior to Screening.
  • Has taken an investigational drug, or used an investigational device, within the previous 4 weeks prior to Screening or plans to take another investigational drug anytime during the study.
  • Is currently following or planning to follow the ketogenic diet.
  • Has been treated with felbamate or vigabatrin within the past 6 months prior to Screening; if a subject has been previously treated with vigabatrin, a visual perimetry test prior to screening (or within the past 6 months) must show normal visual fields or no worsening of recognized visual field abnormalities as compared with prior to vigabatrin treatment.
  • Use of CNS-active medication (other than concomitant AED therapy), unless subjects had been stabilized on such medication for more than 4 weeks prior to Screening.
  • Use of herbal treatments with CNS activity within 4 weeks prior to Screening.
  • Current use of any prohibited concomitant medication as indicated in Section 5.7.2.
  • Is planning surgery to control seizures during the study.
  • Is suffering from acute or progressive neurological disease, severe psychiatric disease, or severe mental abnormalities that, in the investigator's judgment, are likely to interfere with the objectives of the study.
  • Has any medical condition that, in the investigator's judgment, is considered to be clinically significant and could potentially affect subject safety or study outcome, including but not limited to: clinically significant cardiac, renal, hepatic condition, or a condition that affects the absorption, distribution, metabolism or excretion of drugs.
  • Has an average QTc ≥ 450 msec or ≥ 480 msec for subjects with Bundle Branch Block at the time of Screening.

Note: If the initial electrocardiogram (ECG) at Screening indicates a corrected QT (QTc) interval outside these limits, two further ECGs should be performed and the average QTc value of these triplicate ECGs calculated. If the average value exceeds the stated limits, the subject is not eligible.

  • Has active suicidal plan/intent or has had active suicidal thoughts in the past 6 months. Has history of suicide attempt in the last 2 years or more than one lifetime suicide attempt.
  • Has positive test results for hepatitis B surface antigen, positive hepatitis C virus, or human immunodeficiency virus (HIV)-1 or -2 at Screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01607346

United States, Arkansas
GSK Investigational Site
Little Rock, Arkansas, United States, 72205
United States, California
GSK Investigational Site
Los Angeles, California, United States, 90073
United States, Indiana
GSK Investigational Site
Fort Wayne, Indiana, United States, 46804
United States, Maryland
GSK Investigational Site
Bethesda, Maryland, United States, 20817
GSK Investigational Site
Ellicott City, Maryland, United States, 21042
United States, Michigan
GSK Investigational Site
Farmington Hills, Michigan, United States, 48334
United States, Ohio
GSK Investigational Site
Columbus, Ohio, United States, 43210
United States, Pennsylvania
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19107
United States, Texas
GSK Investigational Site
Arlington, Texas, United States, 76017
GSK Investigational Site
Dallas, Texas, United States, 75251
GSK Investigational Site
Temple, Texas, United States, 76508
United States, Wisconsin
GSK Investigational Site
Madison, Wisconsin, United States, 53715
GSK Investigational Site
Dijon, France, 21000
GSK Investigational Site
Montlucon, France, 3100
GSK Investigational Site
Rennes Cedex, France, 35033
GSK Investigational Site
Strasbourg, France, 67091
GSK Investigational Site
Krakow, Poland, 31-209
GSK Investigational Site
Warszawa, Poland, 02-957
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT01607346     History of Changes
Other Study ID Numbers: 116158
Study First Received: May 17, 2012
Last Updated: April 9, 2017

Keywords provided by GlaxoSmithKline:
Urinary Retention

Additional relevant MeSH terms:
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017